Acute myeloid leukemia (AML) is a malignant hematological disease that has shown an increased prevalence in recent years. Despite advancements in treatment, significant limitations remain. Therefore, more information about AML mechanisms is essential to improve therapeutic strategies.

Methods

RT-qPCR, IHC, and western blot were used to analyze SPAG6 expression levels. The association between SPAG6 expression and patient survival was evaluated using LeukemiaDB, GEPIA, and Bloodspot databases. Cell viability was detected by CCK-8 assay. Flow cytometry was applied to measure cell apoptosis and cell cycle.

Results

Database analysis revealed elevated SPAG6 expression in AML. Subsequent RT-qPCR confirmed high SPAG6 expression in AML, MDS, MPN, and ALL samples. Clinical data analysis demonstrated a positive correlation between SPAG6 expression and risk stratification in AML patients. Notably, it was found that the overall survival time of AML patients with high SPAG6 expression was shorter than that of patients with low SPAG6 expression. Moreover, SPAG6 knockdown in the AML cell line HL60 promoted apoptosis and arrested the cell cycle in the G1 phase.

Conclusion

Therefore, we believe that SPAG6 may be a pro-tumor factor in AML.

Open Research

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Supporting Information

References

1A. Khwaja, M. Bjorkholm, R. E. Gale, et al., “Acute Myeloid Leukaemia,” Nature Reviews Disease Primers 2 (2016): 16010.
10.1038/nrdp.2016.10
PubMed Web of Science® Google Scholar
2S. Shimony, M. Stahl, and R. M. Stone, “Acute Myeloid Leukemia: 2023 Update on Diagnosis, Risk-Stratification, and Management,” American Journal of Hematology 98, no. 3 (2023): 502–526.
10.1002/ajh.26822
PubMed Web of Science® Google Scholar
3J. L. Roman Diaz, M. Vazquez Martinez, and F. Khimani, “New Approaches for the Treatment of AML Beyond the 7 + 3 Regimen: Current Concepts and New Approaches,” Cancers (Basel) 16, no. 3 (2024): 677.
10.3390/cancers16030677
CAS PubMed Google Scholar
4T. Sauerer, G. F. Velázquez, and C. Schmid, “Relapse of Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation: Immune Escape Mechanisms and Current Implications for Therapy,” Molecular Cancer 22, no. 1 (2023): 180.
10.1186/s12943-023-01889-6
PubMed Web of Science® Google Scholar
5X. Wang, Y. Zhang, and S. Xue, “Recent Progress in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia,” Annals of Hematology 103 (2024): 1843–1857.
10.1007/s00277-023-05601-y
CAS PubMed Web of Science® Google Scholar
6L. I. Neilson, P. A. Schneider, P. G. Van Deerlin, et al., “cDNA Cloning and Characterization of a Human Sperm Antigen (SPAG6) With Homology to the Product of the Chlamydomonas PF16 Locus,” Genomics 60, no. 3 (1999): 272–280.
10.1006/geno.1999.5914
CAS PubMed Web of Science® Google Scholar
7L. Lee, D. R. Campagna, J. L. Pinkus, et al., “Primary Ciliary Dyskinesia in Mice Lacking the Novel Ciliary Protein Pcdp1,” Molecular and Cellular Biology 28, no. 3 (2008): 949–957.
10.1128/MCB.00354-07
CAS PubMed Web of Science® Google Scholar
8L. F. Cooley, M. E. El Shikh, W. Li, et al., “Impaired Immunological Syapse in Sperm Associated Antigen 6 (SPAG6) Deficient Mice,” Scientific Reports 6 (2016): 25840.
10.1038/srep25840
CAS PubMed Web of Science® Google Scholar
9M. A. Bogoyevitch, Y. Y. Yeap, Z. Qu, et al., “WD40-Repeat Protein 62 Is a JNK-Phosphorylated Spindle Pole Protein Required for Spindle Maintenance and Timely Mitotic Progression,” Journal of Cell Science 125, no. 21 (2012): 5096–5109.
PubMed Web of Science® Google Scholar
10W. Li, A. Mukherjee, J. Wu, et al., “Sperm Associated Antigen 6 (SPAG6) Regulates Fibroblast Cell Growth, Morphology, Migration and Ciliogenesis,” Scientific Reports 5, no. 1 (2015): 16506, https://doi.org/10.1038/srep16506.
10.1038/srep16506
CAS PubMed Google Scholar
11M. Schwander, B. Kachar, and U. Müller, “Review Series: The Cell Biology of Hearing,” Journal of Cell Biology 190, no. 1 (2010): 9–20.
10.1083/jcb.201001138
CAS PubMed Web of Science® Google Scholar
12Z. Bao, R. Zhu, H. Fan, et al., “Aberrant Expression of SPAG6 and NM23 Predicts Poor Prognosis of Human Osteosarcoma,” Frontiers in Genetics 13 (2022): 1012548.
10.3389/fgene.2022.1012548
CAS PubMed Web of Science® Google Scholar
13M. Coan, G. L. Rampioni Vinciguerra, L. Cesaratto, et al., “Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer,” International Journal of Molecular Sciences 19, no. 9 (2018): 2512.
10.3390/ijms19092512
PubMed Web of Science® Google Scholar
14C. Altenberger, G. Heller, B. Ziegler, et al., “SPAG6 and L1TD1 Are Transcriptionally Regulated by DNA Methylation in Non-Small Cell Lung Cancers,” Molecular Cancer 16, no. 1 (2017): 1.
10.1186/s12943-016-0568-5
PubMed Web of Science® Google Scholar
15J. Mijnes, J. Tiedemann, J. Eschenbruch, et al., “SNiPER: A Novel Hypermethylation Biomarker Panel for Liquid Biopsy Based Early Breast Cancer Detection,” Oncotarget 10, no. 60 (2019): 6494–6508, https://doi.org/10.18632/oncotarget.27303.
10.18632/oncotarget.27303
PubMed Google Scholar
16B. Zhao, J. Yin, L. Ding, et al., “SPAG6 Regulates Cell Proliferation and Apoptosis via TGF-β/Smad Signal Pathway in Adult B-Cell Acute Lymphoblastic Leukemia,” International Journal of Hematology 119, no. 2 (2024): 119–129, https://doi.org/10.1007/s12185-023-03684-x.
10.1007/s12185-023-03684-x
CAS PubMed Google Scholar
17M. R. Abdel Hammed, Y. A. Ahmed, E. N. Adam, et al., “sVCAM-1, and TGFβ1 in Chronic Phase, Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors,” Egyptian Journal of Immunology 29, no. 4 (2022): 163–173.
10.55133/eji.290416
PubMed Google Scholar
18Y. Hu, X. Cao, Y. Zhao, et al., “The Function of Spag6 to Repair Brain Edema Damage After Cerebral Ischemic Stroke-Reperfusion,” Neuroscience 522 (2023): 132–149.
10.1016/j.neuroscience.2023.04.014
CAS PubMed Web of Science® Google Scholar
19D. Mohammed, S. Khallaf, M. El-Naggar, et al., “Interleukin-10: A Potential Prognostic Marker in Patients With Newly Diagnosed Multiple Myeloma,” Research in Oncology 17, no. 1 (2021): 38–41.
10.21608/resoncol.2021.51503.1127
Google Scholar
20M. Jiang, Y. Chen, L. Deng, et al., “Upregulation of SPAG6 in Myelodysplastic Syndrome: Knockdown Inhibits Cell Proliferation via AKT/FOXO Signaling Pathway,” DNA and Cell Biology 38, no. 5 (2019): 476–484.
10.1089/dna.2018.4521
CAS PubMed Web of Science® Google Scholar
21J. Luo, J. Mu, M. Zhang, et al., “SPAG6-Silencing Enhances Decitabine-Induced Apoptosis and Demethylation of PTEN in SKM-1 Cells and in a Xenograft Mouse Model,” Leukemia & Lymphoma 62, no. 9 (2021): 2242–2252.
10.1080/10428194.2021.1913148
CAS PubMed Web of Science® Google Scholar
22M. E. Teves, Z. Zhang, R. M. Costanzo, et al., “Sperm-Associated Antigen-17 Gene Is Essential for Motile Cilia Function and Neonatal Survival,” American Journal of Respiratory Cell and Molecular Biology 48, no. 6 (2013): 765–772.
10.1165/rcmb.2012-0362OC
CAS PubMed Web of Science® Google Scholar
23D. F. Zheng, Q. Wang, J. P. Wang, et al., “The Emerging Role of Sperm-Associated Antigen 6 Gene in the Microtubule Function of Cells and Cancer,” Molecular Therapy - Oncolytics 15 (2019): 101–107.
10.1016/j.omto.2019.08.011
CAS PubMed Web of Science® Google Scholar
24M. O. Kitchen, R. T. Bryan, K. E. Haworth, et al., “Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer,” PLoS One 10, no. 9 (2015): e0137003.
10.1371/journal.pone.0137003
PubMed Web of Science® Google Scholar
25M. A. Mulaw, A. Krause, A. J. Deshpande, et al., “CALM/AF10-Positive Leukemias Show Upregulation of Genes Involved in Chromatin Assembly and DNA Repair Processes and of Genes Adjacent to the Breakpoint at 10p12,” Leukemia 26, no. 5 (2012): 1012–1019, https://doi.org/10.1038/leu.2011.307.
10.1038/leu.2011.307
CAS PubMed Web of Science® Google Scholar
26D. Steinbach, A. Schramm, A. Eggert, et al., “Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia,” Clinical Cancer Research 12, no. 8 (2006): 2434–2441.
10.1158/1078-0432.CCR-05-2552
CAS PubMed Web of Science® Google Scholar
27D. Steinbach, P. Bader, A. Willasch, et al., “Prospective Validation of a New Method of Monitoring Minimal Residual Disease in Childhood Acute Myelogenous Leukemia,” Clinical Cancer Research 21, no. 6 (2015): 1353–1359.
10.1158/1078-0432.CCR-14-1999
CAS PubMed Web of Science® Google Scholar
28I. Marjanovic, T. Karan-Djurasevic, M. Ugrin, et al., “Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients,” Clinical Lymphoma, Myeloma & Leukemia 17, no. 5 (2017): 312–319.
10.1016/j.clml.2016.12.006
PubMed Web of Science® Google Scholar
29S. Aref, S. El Sharawy, M. Sabry, et al., “Prognostic Relevance of Wilms Tumor 1 (WT1) Gene Exon 7 Mutations In-Patient With Cytogenetically Normal Acute Myeloid Leukemia,” Indian Journal of Hematology and Blood Transfusion 30, no. 4 (2014): 226–230.
10.1007/s12288-013-0288-6
PubMed Web of Science® Google Scholar
30A. Asghari-Ghomi, F. Fallahian, J. Garavand, et al., “WT1 and TP53 as Valuable Diagnostic Biomarkers for Relapse After Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia,” Molecular Biology Reports 51, no. 1 (2024): 244.
10.1007/s11033-023-09185-8
CAS PubMed Web of Science® Google Scholar
31M. R. Abdel Hammed, H. A. El-Amien, M. N. Asham, et al., “Can Platelets Indices and Blood Neutrophil to Lymphocyte Ratio Be Used as Predictors for Diagnosis of Spontaneous Bacterial Peritonitis in Decompensated Post Hepatitis Liver Cirrhosis?,” Egyptian Journal of Immunology 29, no. 4 (2022): 12–24.
10.55133/eji.290402
PubMed Google Scholar
32Q. Zhang, Q. Yang, Y. Weng, et al., “Neutrophil-To-Lymphocyte Ratio Correlates With Prognosis and Response to Chemotherapy in Patients With Non-M3 De Novo Acute Myeloid Leukemia,” Translational Cancer Research 10, no. 2 (2021): 1013–1024.
10.21037/tcr-20-2179
PubMed Web of Science® Google Scholar
33M. R. Abd El-Hameed and A. M. Abozied, “Mean Platelet Volume in Impaired Fasting Glucose Subjects and Diabetic Patients as a Risk Factor for Thrombotic Complications,” Journal of American Science 9, no. 9 (2013): 12–17.
Google Scholar
34M. Tığlıoğlu, M. Albayrak, S. Doğan, et al., “Mean Platelet Volume Is a Predictive and Prognostic Marker for Patients With Acute Myeloid Leukemia: A Two-Center Retrospective Analysis,” Leukemia & Lymphoma 62, no. 11 (2021): 2755–2761, https://doi.org/10.1080/10428194.2021.1929962.
10.1080/10428194.2021.1929962
CAS PubMed Web of Science® Google Scholar
35M. R. Abdel Hammed, M. A. Tohamy, S. Z. Boshra, et al., “Red Cell Distribution Width Is an Inflammatory Predictor Marker of Contrast Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention,” Egyptian Journal of Immunology 30, no. 3 (2023): 1–12.
10.55133/eji.300301
PubMed Google Scholar
36V. Vucinic, L. Ruhnke, K. Sockel, et al., “The Diagnostic Red Blood Cell Distribution Width as a Prognostic Factor in Acute Myeloid Leukemia,” Blood Advances 5, no. 24 (2021): 5584–5587, https://doi.org/10.1182/bloodadvances.2021005974.
10.1182/bloodadvances.2021005974
PubMed Web of Science® Google Scholar
37I. De Kouchkovsky and M. Abdul-Hay, “Acute Myeloid Leukemia: A Comprehensive Review and 2016 Update,” Blood Cancer Journal 6, no. 7 (2016): e441.
10.1038/bcj.2016.50
CAS PubMed Web of Science® Google Scholar
38J. P. Patel, M. Gönen, M. E. Figueroa, et al., “Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia,” New England Journal of Medicine 366, no. 12 (2012): 1079–1089, https://doi.org/10.1056/NEJMoa1112304.
10.1056/NEJMoa1112304
CAS PubMed Web of Science® Google Scholar
39H. Döhner, E. H. Estey, S. Amadori, et al., “Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations From an International Expert Panel, on Behalf of the European LeukemiaNet,” Blood 115, no. 3 (2010): 453–474.
10.1182/blood-2009-07-235358
CAS PubMed Web of Science® Google Scholar
40K. Mrózek, G. Marcucci, D. Nicolet, et al., “Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia,” Journal of Clinical Oncology 30, no. 36 (2012): 4515–4523, https://doi.org/10.1200/JCO.2012.43.4738.
10.1200/JCO.2012.43.4738
PubMed Web of Science® Google Scholar

Volume47, Issue4

August 2025

Pages 680-689

High Expression of SPAG6 Acts as a Pro-Tumor Factor and Associated With Poor Prognosis in Acute Myeloid Leukemia

ABSTRACT

Background

Methods

Results

Conclusion

Open Research

Data Availability Statement

Supporting Information

References

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

High Expression of SPAG6 Acts as a Pro-Tumor Factor and Associated With Poor Prognosis in Acute Myeloid Leukemia

ABSTRACT

Background

Methods

Results

Conclusion

Open Research

Data Availability Statement

Supporting Information

References

References

Related

Information